MNG438
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.522
- TNFA_SIGNALING_VIA_NFKB+0.369
- COAGULATION+0.285
- ESTROGEN_RESPONSE_EARLY+0.274
- ESTROGEN_RESPONSE_LATE+0.236
- APICAL_JUNCTION+0.219
- ANDROGEN_RESPONSE+0.218
- UV_RESPONSE_DN+0.216
- MYOGENESIS+0.207
- KRAS_SIGNALING_UP+0.195
Top 10 suppressed
- MYC_TARGETS_V2-0.537
- E2F_TARGETS-0.487
- G2M_CHECKPOINT-0.411
- MYC_TARGETS_V1-0.382
- OXIDATIVE_PHOSPHORYLATION-0.374
- DNA_REPAIR-0.213
- UNFOLDED_PROTEIN_RESPONSE-0.213
- MTORC1_SIGNALING-0.210
- ALLOGRAFT_REJECTION-0.209
- CHOLESTEROL_HOMEOSTASIS-0.066
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG421 | — | — | 0.887 |
| 2 | 4c7083b3-eccc-4d80-a31d-6fd3cd0222b4 | — | — | 0.879 |
| 3 | TCGA-A2-A0ES-01A-11R-A115-07 | — | A | 0.872 |
| 4 | MNG117 | — | — | 0.870 |
| 5 | TCGA-K4-A4AB-01B-12R-A28M-07 | — | — | 0.866 |
| 6 | TCGA-50-6673-01A-11R-1949-07 | — | cohortA1 | 0.861 |
| 7 | TCGA-55-7284-01B-11R-2241-07 | — | cohortA1 | 0.857 |
| 8 | MNG359 | — | — | 0.855 |
| 9 | ULC1729T_S65 | — | cohortSQ1 | 0.844 |
| 10 | SRR1313091 | — | A | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.522 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.369 | Inavolisib | — uncovered |
| COAGULATION | 0.285 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.274 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.236 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.219 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.218 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.216 | Inavolisib | — uncovered |
| MYOGENESIS | 0.207 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.195 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.193 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.183 | Inavolisib | — uncovered |
| HYPOXIA | 0.175 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.153 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.143 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.142 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.131 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.124 | Idelalisib | — uncovered |